

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer ID6310

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company Bristol-Myers Squibb (nivolumab) Patient/carer groups Asthma and Lung UK Black Health Agency for Equality Cancer Black Care Cancer Equality	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission
 Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Oncogene-Driven Lung Cancer Patient Alliance UK Roy Castle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition 	 Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Healthcare professional groups Association of Anaesthetists Association of Cancer Physicians Association of Respiratory Nurse Specialists Association of Surgeons of Great Britain and Ireland British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society British Society of Interventional Radiology British Thoracic Oncology Group 	 Possible comparator companies Aspire Pharma (pemetrexed) AstraZeneca (durvalumab, osimertinib) Bristol Myers Squibb (nivolumab, paclitaxel) Dr Reddy's Laboratories (pemetrexed) Eli Lilly (pemetrexed) Genus Pharmaceuticals (pemetrexed) Medac (oxaliplatin) Merck Sharp & Dohme UK (pembrolizumab) Pfizer (cisplatin, carboplatin, docetaxel, oxaliplatin, paclitaxel, pemetrexed) Ranbaxy (oxaliplatin) Roche (atezolizumab)

Provisional stakeholder list for the evaluation of nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer ID6310 Issue date: January 2024



Consultees	Commentators (no right to submit or
	appeal)
 British Thoracic Society British Transplantation Society Cancer Research UK Lung Cancer and Mesothelioma Clinical Expert Group Lung Cancer Nursing UK National Heart and Lung Institute NHS Blood and Transplant Primary Care Respiratory Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Sandoz (cisplatin, pemetrexed) Seacross Pharmaceuticals (paclitaxel, oxaliplatin, docetaxel) Teva UK (paclitaxel) Zentiva (pemetrexed) Relevant research groups Cochrane Lung Cancer Group Cochrane UK Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer ID6310 Issue date: January 2024





All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.